HCM
ADPT icon

Highline Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Highline Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-57,081
Closed -$2.76M – 19
2020
Q2 		$2.76M Buy
+57,081
New +$2.08M 2.24% 17
2019
Q3 		– Sell
-121,000
Closed -$5.84M – 27
2019
Q2 		$5.84M Buy
+121,000
New +$5.36M 0.43% 29

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

Highline Capital Management's ADPT Position: Q3 2020 in Review

Highline Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q3 2020, closing a stake of 57,081 shares — an estimated $2.76M sold.

Highline Capital Management first reported a position in ADPT in Q2 2019 and held it in 2 quarters. The position peaked at $5.84M in Q2 2019. 206 funds tracked by Wall St. Rank hold ADPT as of Q3 2020.

  • Highline Capital Management reported no remaining Adaptive Biotechnologies position as of Q3 2020 after selling out during the quarter.
  • Highline Capital Management sold 57,081 Adaptive Biotechnologies shares in Q3 2020, an estimated $2.76M.
  • Highline Capital Management first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 2 quarters.
  • Highline Capital Management's Adaptive Biotechnologies position peaked at $5.84M in Q2 2019.
  • 206 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2020.

Based on Highline Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.